A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma
Table 4
Baseline characteristics.
BOLT, sonidegib 200 mg
ERIVANCE, vismodegib 150 mg
Prematched
Postmatched
Matched baseline characteristics
Prior BCC radiotherapy, (%)
5 (7.6%)
(20.6%)
13 (20.6%)
Prior BCC surgery, (%)
48 (72.7%)
(89.0%)
56 (88.9%)
Unmatched baseline characteristics
Age in years
Mean
64.6
64.6
61.4
Median
67.0
67.0
62.0
Standard deviation
15.9
15.5
16.9
Age range in years, (%)
18–40
6 (9.1%)
(8.6%)
7 (11.1%)
41–64
22 (33.3%)
(31.6%)
26 (41.3%)
≥65
38 (57.6%)
(59.8%)
30 (47.6%)
Race, (%)
White
59 (89.4%)
(90.8%)
(100.0%)
Other
7 (10.6%)
(9.2%)
(0.0%)
ECOG status, (%)
0
44 (66.7%)
(69.3%)
48 (76.2%)
1
16 (24.2%)
(21.5%)
13 (20.6%)
2
4 (6.1%)
(6.0%)
2 (3.2%)
Sex, (%)
Male
38 (57.6%)
(60.8%)
35 (55.6%)
Female
28 (42.4%)
(39.2%)
28 (44.4%)
Prior systemic therapy for BCC, (%)
4 (6.1%)
(5.4%)
7 (11.1%)
BCC: basal cell carcinoma; ECOG: Eastern Cooperative Oncology Group. BOLT data analysis was based on the 18-month update (i.e., 18 months of patient follow-up) [7]; ERIVANCE summary information was based on the 12-month update (i.e., 21 months of patient follow-up) [16]; postmatched BOLT results were weighted at the person level; therefore, the number of patients was not available; two patients had missing ECOG status at baseline; Systemic or topical.
